|
Post by mindovermatter on Jan 21, 2016 12:29:47 GMT -5
Same thing was said about Sanofi deal. Just want to point that out.
|
|
|
Post by mnkdorbust on Jan 21, 2016 12:52:15 GMT -5
Same thing was said about Sanofi deal. Just want to point that out. I get it to an extent.... Our stock currently needs sonar and Matt included is well underwater on his.
|
|
|
Post by peppy on Jan 21, 2016 12:57:45 GMT -5
From the words, this licensing agreement was probably the licensing agreement that Hakan talked about on his last CC as CEO.
|
|
|
Post by LosingMyBullishness on Jan 21, 2016 14:03:43 GMT -5
Guess there will be some junior members from SA bashers like LFD and Orange Peel Investment circling around at Receptor's address in Seattle to get some photos and information.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 21, 2016 17:43:01 GMT -5
This deal demonstrates that TS is a great drug delivery technology. Unfortunately, Wall Street is making this out to be insignificant, however, if one considers the potential of the deal, it could eliminate all of MannKind's debt. That is no joke.
|
|
|
Post by factspls88 on Jan 21, 2016 18:02:20 GMT -5
Note that Matt refers to partner " companies." Was this in the plural because there is more than one company participating in the partnership? Or did Matt just mean this as a general statement?
|
|
|
Post by bioexec25 on Jan 21, 2016 18:10:09 GMT -5
It is possible Facts that this is a collaboration between companies interested in inhalation technologies. It is also feasible that they don't want their identities disclosed just yet but are allowing Mnkd some early press.
|
|
|
Post by od on Jan 21, 2016 18:15:17 GMT -5
It is possible Facts that this is a collaboration between companies interested in inhalation technologies. It is also feasible that they don't want their identities disclosed just yet but are allowing Mnkd some early press. Interesting notion, but...if the collaborators were significant companies there would probably be upfront fees.
|
|
|
Post by falconquest on Jan 21, 2016 18:41:27 GMT -5
"We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products," said Matthew Pfeffer, Chief Executive Officer of MannKind.
files.shareholder.com/downloads/AMDA-22AIJ9/1382043805x0x870992/be295beb-3046-46ff-90f0-d50ad4748b16/MNKD_News_2016_1_21_General_Releases.pdf
Note that Matt does not say "OUR portfolio of innovative inhaled products"? It appears that this is an agreement with a company that has plans to use the Technosphere delivery system (developed by MannKind Corporation) to develop its own inhalable product line. This could mean the API are likely not any that were listed at the JPM Conference.
--
About Receptor Life Sciences, Inc. Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. It's that last line... About Receptor Life Sciences, Inc. Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. The first thing that came to mind after reading this is, there is some money behind this. "Laying the foundation", "groundbreaking", "specialty pharmaceutical", something is up here that is not at all obvious. It will be interesting to see how this plays out.
|
|
|
Post by od on Jan 21, 2016 20:34:11 GMT -5
"We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products," said Matthew Pfeffer, Chief Executive Officer of MannKind.
files.shareholder.com/downloads/AMDA-22AIJ9/1382043805x0x870992/be295beb-3046-46ff-90f0-d50ad4748b16/MNKD_News_2016_1_21_General_Releases.pdf
Note that Matt does not say "OUR portfolio of innovative inhaled products"? It appears that this is an agreement with a company that has plans to use the Technosphere delivery system (developed by MannKind Corporation) to develop its own inhalable product line. This could mean the API are likely not any that were listed at the JPM Conference.
--
About Receptor Life Sciences, Inc. Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. It's that last line... About Receptor Life Sciences, Inc. Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. The first thing that came to mind after reading this is, there is some money behind this. "Laying the foundation", "groundbreaking", "specialty pharmaceutical", something is up here that is not at all obvious. It will be interesting to see how this plays out. I hope as much as anyone that Receptor is significant. Strong phrases/buzzwords for a Newco to 'declare victory' - nothing new here (to me).
|
|
|
Post by rvc on Jan 21, 2016 21:38:03 GMT -5
looks suspicious as hell to me
|
|
|
Post by lakers on Jan 22, 2016 12:47:50 GMT -5
Hakan said they worked w/ some major portfolio management company. Inflamarory disorder means Rheumatoid Arthritis. Neurologic disease means Multiple Sclerosis. 9:01 am Mannkind enters into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences (MNKD) : The co announced that it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, Inc., pursuant to which multiple inhaled therapeutic products will be developed to explore their potential to treat conditions such as chronic pain, neurologic diseases and inflammatory disorders. Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product. Spasticity refers to feelings of stiffness and a wide range of involuntary muscle spasms (sustained muscle contractions or sudden movements). It is one of the more common symptoms of MS. Spasticity may be as mild as the feeling of tightness of muscles or may be so severe as to produce painful, uncontrollable spasms of extremities, usually of the legs. Spasticity may also produce feelings of pain or tightness in and around joints, and can cause low back pain. Although spasticity can occur in any limb, it is much more common in the legs. Spasticity is a condition in which certain muscles are continuously contracted. This contraction causes stiffness or tightness of the muscles and can interfere with normal movement, speech, and gait. Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. Who is the licensing agreement with? The licensing agreement is between MannKind and Receptor Life Sciences, Inc., an independent company, not affiliated with MannKind. The company is private and newly formed under this name. We can confirm that the company is funded by an important investor group, supported by prominent business leaders in the Seattle area. Alfred Mann is not an investor or in any way affiliated with Receptor. MannKind did significant diligence in regards to Receptor and its financial backers, and came away quite impressed. But the underlying investors, for good reasons of their own, need not and choose not to disclose their involvement at this time. How will Technosphere technology be used by the licensee? Technosphere technology is to be used as a vehicle to deliver regulated doses of a proprietary compound to treat a variety of medical conditions, including chronic pain, spasticity and inflammatory diseases such as rheumatoid arthritis. What are the benefits of using MannKind’s technology for the licensee? Technosphere’s value proposition is the immediate delivery of a consistent and precise dosage of the prescribed amount of an active therapeutic compound, while reducing unwanted side effects. In addition, MannKind’s inhalers are convenient, discreet and easy-to-use from patients’ perspective as well as being a robust and low-cost delivery system from a manufacturing perspective. What are the financial terms of the agreement? Under the terms of the licensing agreement, Mannkind is eligible to receive up to $102.25 million in milestone payments. Additionally, MannKind will receive royalties paid on sales of the product. Those royalties are tiered based on sales volumes, and range from the mid-single digits at lower volumes to low double digits at higher volumes. Is the agreement exclusive in any way? The agreement is exclusive only to the compounds used by the licensee, which are proprietary to them in any case. It does not prevent us from entering into other licensing agreements with other companies, even in the same therapeutic area, so long as they use different active compounds. [As I had said licensee wanted to develop MS and Rheumatoid Athritis - 2 huge mkts. Paul Allen, MSFT founder, might be one of investors. Gates Foundation might be another.] www.mannkindcorp.com/Collateral/Documents/English-US/TS%20licensing%20FAQ.pdf
|
|
|
Post by beardawg on Jan 25, 2016 10:55:35 GMT -5
Same thing was said about Sanofi deal. Just want to point that out. The difference here is that Mannkind is not really going to be involved in the product. It will be Receptor's own product. Mannkind won't even produce it. It'll be pretty much hands off. The Sanofi deal was a true partnership where they are working together because it was Mannkind's product. It's like if a company licenses their software for use in a car. They pretty much just say they get royalty from the company for it. They don't have to go into detail about what the company is doing with the car or other parts, and they likely won't even have that info from the car company, either.
|
|
|
Post by dictatorsaurus on Jan 25, 2016 12:39:54 GMT -5
Many speculations floating around on who Receptor is.
Closest guess??
|
|
|
Post by bradleysbest on Jan 25, 2016 12:49:07 GMT -5
Gates & his buddies...
|
|